# Shuttle Pharmaceuticals Holdings, Inc.: overview SHPH · Nasdaq · CIK 1757499 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/shph.md) · [Financials](/companies/shph/financials.md) · [Filings](/companies/shph/filings.md) · [Insiders](/companies/shph/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(39.83)](/filings/0001493152-25-022162.md) | not reported | [(7.60)](/filings/0001493152-26-023859.md) | [(32.91)](/filings/0001493152-26-044107.md) | [(1.05)](/filings/0001493152-25-022162.md) | not reported | [(0.43)](/filings/0001493152-26-023859.md) | [(3.10)](/filings/0001493152-26-044107.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(5.04)](/filings/0001493152-24-034898.md) | [(3.53)](/filings/0001493152-25-008300.md) | [(82.60)](/filings/0001493152-26-014131.md) | [(7.16)](/filings/0001493152-26-014131.md) | | Free cash flow | $k | not reported | not reported | [(5,600)](/filings/0001493152-25-008300.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/shph/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $79.2k | 24,354 | | New +24,354 | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $2.4k | 750 | | New +750 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $1.3k | 389 | | New +389 | | [KELLEHER FINANCIAL ADVISORS](/funds/1507971.md) | 2026-06-30 | $390 | 120 | | New +120 | | [HRT FINANCIAL LP](/funds/1475597.md) | 2026-06-30 | $255 | 78,597 | | New +78,597 | ## Recent filings [All 307 filings](/companies/shph/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 20:30 ET | [8-K](/filings/0001493152-26-048112.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001493152-26-048112 | | 2026-09-24 | 16:01 ET | [10-Q](/filings/0001493152-26-044107.md) | Quarterly report, period 2026-06-30 | 0001493152-26-044107 | | 2026-09-24 | 16:00 ET | [8-K/A](/filings/0001493152-26-044106.md) | 9.01 Financial statements and exhibits | 0001493152-26-044106 | | 2026-09-16 | 22:15 ET | [8-K](/filings/0001493152-26-042791.md) | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-042791 | | 2026-09-11 | 11:30 ET | [8-K](/filings/0001493152-26-042299.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-042299 | | 2026-09-02 | 19:00 ET | [8-K](/filings/0001493152-26-041213.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-041213 | | 2026-09-01 | 20:05 ET | [8-K](/filings/0001493152-26-041011.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-041011 | | 2026-08-28 | 20:45 ET | [8-K](/filings/0001493152-26-040622.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-040622 | | 2026-08-17 | 21:03 ET | [8-K/A](/filings/0001493152-26-038786.md) | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001493152-26-038786 | | 2026-08-13 | 20:30 ET | [DEF 14A](/filings/0001493152-26-037821.md) | Proxy statement, period 2026-08-13 | 0001493152-26-037821 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-014131.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1757499 - Tickers: SHPH - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.